See more : InsuraGuest Technologies Inc. (ISGI.V) Income Statement Analysis – Financial Results
Complete financial analysis of Cyfuse Biomedical K.K. (4892.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyfuse Biomedical K.K., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- EPL Limited (EPL.BO) Income Statement Analysis – Financial Results
- Bango PLC (BGO.L) Income Statement Analysis – Financial Results
- Idun Industrier AB (publ) (IDUN-B.ST) Income Statement Analysis – Financial Results
- MACOMPTA.FR (MLMCA.PA) Income Statement Analysis – Financial Results
- California Grapes International, Inc. (CAGR) Income Statement Analysis – Financial Results
Cyfuse Biomedical K.K. (4892.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cyfusebio.com
About Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 61.11M | 374.48M | 708.25M | 137.48M |
| Cost of Revenue | 23.37M | 132.98M | 137.64M | 70.46M |
| Gross Profit | 37.74M | 241.50M | 570.60M | 67.02M |
| Gross Profit Ratio | 61.76% | 64.49% | 80.57% | 48.75% |
| Research & Development | 375.00M | 303.00M | 266.49M | 242.59M |
| General & Administrative | 108.00M | 95.00M | 0.00 | 0.00 |
| Selling & Marketing | 243.00M | 251.00M | 0.00 | 0.00 |
| SG&A | 351.00M | 346.00M | 500.00M | 439.00M |
| Other Expenses | 9.18M | 37.44M | 79.41M | 50.43M |
| Operating Expenses | 735.18M | 666.59M | 500.03M | 439.16M |
| Cost & Expenses | 758.55M | 799.57M | 637.68M | 509.62M |
| Interest Income | 40.00K | 41.00K | 176.00K | 148.00K |
| Interest Expense | 9.77M | 27.93M | 5.24M | 5.93M |
| Depreciation & Amortization | 38.12M | 54.29M | 18.50M | 32.89M |
| EBITDA | -538.29M | -410.21M | 168.65M | -288.66M |
| EBITDA Ratio | -880.82% | -93.72% | 23.81% | -209.96% |
| Operating Income | -697.44M | -425.09M | 70.57M | -372.14M |
| Operating Income Ratio | -1,141.24% | -113.52% | 9.96% | -270.68% |
| Total Other Income/Expenses | 111.25M | -46.86M | 74.35M | 44.64M |
| Income Before Tax | -586.19M | -471.95M | 144.91M | -327.49M |
| Income Before Tax Ratio | -959.20% | -126.03% | 20.46% | -238.20% |
| Income Tax Expense | 3.02M | 2.01M | 2.01M | 2.01M |
| Net Income | -589.21M | -473.96M | 142.91M | -329.50M |
| Net Income Ratio | -964.15% | -126.57% | 20.18% | -239.66% |
| EPS | -75.42 | -177.67 | 285.52 | -46.12 |
| EPS Diluted | -75.42 | -177.67 | 285.52 | -46.12 |
| Weighted Avg Shares Out | 7.81M | 2.67M | 500.50K | 7.14M |
| Weighted Avg Shares Out (Dil) | 7.81M | 2.67M | 500.50K | 7.14M |
Source: https://incomestatements.info
Category: Stock Reports